New stroke drug shows promise in early trial

This study tests a new drug called MT200605 in 360 people who have had an acute ischemic stroke within the past 24 hours. The drug aims to protect brain cells and reduce damage from the stroke. Participants will receive either a high, medium, or low dose of the drug or a placebo, along with standard care. The main goal is to see if more people can recover to near-normal function (measured by a score of 0 or 1 on the modified Rankin Scale) three months after the stroke.